Do you offer local consolidative therapy for patients with polymetastatic driver mutation-positive NSCLC who respond well to targeted therapy?  

If so, when and to what extent? 

Answer from: Medical Oncologist at Academic Institution
Radiation Oncologist at National Cancer Institute
The question was about polymetastatic, driver-muta...
Radiation Oncologist at UCLA | VA Greater Los Angeles Healthcare System
@Vik is right. There is a paucity of data to guide...
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution